GlassScriptPhysician profile
Zaki Lababidi
NPI 1225039183
$7,264.96
in general payments reported to CMS, 2019-2025
41 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,641 · 2020: $294 · 2021: $253 · 2022: $562 · 2023: $1,147 · 2024: $1,262 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.76 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,001.49 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $616.74 | 2019-2023 | Xarelto |
| Amgen INC. | $614.80 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $537.35 | 2019-2025 | Andexxa, Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $526.71 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.18 | 2019-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $342.22 | 2023-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $324.28 | 2019-2025 | Eliquis, Camzyos |
| Heartflow, INC. | $294.46 | 2023-2025 | Ffrct |
| Edwards Lifesciences Corporation | $283.20 | 2019-2025 | Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $255.65 | 2019-2025 | Opsumit, Uptravi |
| Pfizer INC. | $232.06 | 2019-2025 | |
| Bardy Diagnostics, INC. | $160.23 | 2019-2021 | |
| Astellas Pharma US INC | $159.27 | 2019 | |
| Amarin Pharma, INC. | $133.12 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaki Lababidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.